Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Ariad Pharmaceuticals |
---|---|
Information provided by: | Ariad Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00110188 |
The purpose of this study is to assess the antitumor activity of weekly AP23573 study treatment in patients with taxane-resistant AIPC.
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer |
Drug: AP23573 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Study of the Efficacy and Safety of AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC) |
Enrollment: | 38 |
Study Start Date: | May 2005 |
Study Completion Date: | August 2007 |
Primary Completion Date: | August 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
50 mg of AP23573 intravenously over 30 minutes, weekly
|
Drug: AP23573
50 mg of AP23573 intravenously over 30 minutes, weekly
|
The primary objective of this phase II study is to assess the anti-cancer activity of weekly AP23573 administration in patients with taxane-resistant AIPC. Other objectives include evaluating experimental parameters that may predict or indicate response to mTOR inhibition, such as effects on plasma VEGF, markers of tumoral PI3K/mTOR-pathway activity, and proteomic analysis. The inclusion of these evaluations in this trial may provide insight into the identification of markers that may be helpful in optimizing AP23573 treatment and in identifying patients with AP23573-sensitive tumors.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Louis Warchaw Prostate Cancer Center, Cedars-Sinai Medical Center | |
Los Angeles, California, United States, 90048 | |
United States, Massachusetts | |
Beth Israel Deaconess Medical Center/MGH/DFCI | |
Boston, Massachusetts, United States, 02215 | |
United States, Texas | |
The Methodist Hospital Research Institute | |
Houston, Texas, United States, 77030 | |
United States, Wisconsin | |
University of Wisconsin, Madison, WI | |
Madison, Wisconsin, United States, 53792 |
Study Director: | Frank Haluska, M.D. | Ariad Pharmaceuticals |
Responsible Party: | ARIAD Pharmaceuticals, Inc. ( Frank Haluska, M.D. ) |
Study ID Numbers: | AP23573-04-204 |
Study First Received: | May 4, 2005 |
Last Updated: | September 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00110188 |
Health Authority: | United States: Food and Drug Administration |
prostate cancer |
Prostatic Diseases Genital Neoplasms, Male Urogenital Neoplasms |
Genital Diseases, Male Taxane Prostatic Neoplasms |
Neoplasms Neoplasms by Site |